Medlumics
MedLumics is a Madrid-based medical device company developing the AblaView® System, which uses proprietary optical reflectometry to provide real-time tissue guidance during cardiac ablation procedures for atrial fibrillation at hospitals and electrophysiology labs.
- Company typePrivate
- Founded2009
- HeadquartersMadrid, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Medlumics firmographics
Firmographics- Name
- Medlumics
- Website
- https://medlumics.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MedLumics is a Madrid-based medical device company developing the AblaView® System, which uses proprietary optical reflectometry to provide real-time tissue guidance during cardiac ablation procedures for atrial fibrillation at hospitals and electrophysiology labs.
- Ownership category
- akta.pro rank
Medlumics industry classification
Industry- Product category
- Cardiac Electrophysiology Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Electrophysiology Mapping & Ablation Systems (HLAHAFAD)
- akta.pro secondary industries
- Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG), Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)
Keywords
Where Medlumics is headquartered
LocationHeadquarters
- HQ city
- Madrid
- HQ country
- Spain
- HQ region
- Europe
Markets served
Medlumics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Medlumics product offering
Product offeringCore offering
Medlumics develops the AblaView® System, a medical device that uses optical reflectometry technology to provide real-time optical guidance during cardiac ablation procedures for the treatment of atrial fibrillation (AF). The system is designed to improve procedural safety and reduce arrhythmia recurrence rates by enabling physicians to visualize tissue response and ensure complete lesions while minimizing collateral damage to surrounding cardiac tissue.
Differentiator
Problem solved
Functional benefit
Brands
- AblaView®: Real-time optical-guided ablation system for treatment of atrial fibrillation using optical reflectometry technology to improve safety and reduce recurrence.
Products and services
- AblaView® System A medical device system for real-time optical-guided ablation treatment of atrial fibrillation (AF). The system uses optical reflectometry technology to enable physicians to visualize tissue response during ablation, ensuring complete lesions while minimizing collateral damage to surrounding cardiac tissue. Designed for electrophysiologists and cardiac ablation centers performing catheter ablation procedures.
Companies that use Medlumics
Customer profileSegments1 record
Ideal customer profiles1 record
Medlumics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Medlumics competitors and assessment
Company assessmentEmerging players
- CardioFocus: Developer of the HeartLight endoscopic ablation system for pulmonary vein isolation in AF, a direct competitor in next-generation AF ablation technologies.
- Stereotaxis: Provides robotic magnetic navigation systems for cardiac ablation procedures, offering a differentiated precision-advancement approach similar in spirit to Medlumics' novel architecture.
- Acutus Medical: Develops electrophysiology mapping and ablation technologies including the AcQMap system that uses non-contact charge density mapping. An emerging direct competitor in novel cardiac mapping approaches.
- Imricor Medical Systems: Develops MRI-guided cardiac ablation catheters and related devices, competing in the novel real-time guidance niche where Medlumics' optical reflectometry also operates.
Broad incumbents
- Medtronic: Markets cardiac ablation and mapping technologies including the DiamondTemp ablation system and Arctic Front cryoablation catheters, competing with AblaView across multiple ablation modalities.
- Boston Scientific: Offers the RHYTHMIA HDx mapping system and a growing portfolio of ablation technologies for atrial fibrillation and ventricular arrhythmias. A direct competitor in 3D cardiac mapping.
- Philips: Provides interventional imaging and image-guided therapy platforms (including interventional cardiology/X-ray systems) used in the same EP lab workflows where AblaView would be deployed.
- Biosense Webster (Johnson & Johnson): Market-leading electrophysiology franchise offering the CARTO 3 mapping system and a broad ablation catheter portfolio used in AF ablation procedures globally. The dominant incumbent that AblaView would need to displace in EP labs.
- Abbott: Sells the EnSite X EP system and a full suite of ablation catheters and diagnostic devices for cardiac arrhythmia treatment. Competes directly with AblaView in cardiac ablation guidance.
Others
- Intravascular Imaging companies (e.g., Infraredx/Canon, Conavi): Companies using optical/intravascular imaging modalities (NIRS, OCT) for tissue characterization in cardiology. Adjacent technology comparators that validate the feasibility of optical tissue sensing in clinical cardiology.
Market position
Customer concentration
Medlumics social profiles
Digital presenceMedlumics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medlumics leadership team
Management profileNumber of profiles
Profiles1 record
Medlumics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medlumics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medlumics
What does Medlumics do?
Medlumics develops the AblaView® System, a medical device that uses optical reflectometry technology to provide real-time optical guidance during cardiac ablation procedures for the treatment of atrial fibrillation (AF). The system is designed to improve procedural safety and reduce arrhythmia recurrence rates by enabling physicians to visualize tissue response and ensure complete lesions while minimizing collateral damage to surrounding cardiac tissue.
Is Medlumics a public or private company?
Medlumics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Medlumics founded?
Medlumics was founded in 2009. It employs 11 to 50 people.
Where is Medlumics based?
Medlumics is headquartered in Madrid, Spain, in the Europe region.
Who are Medlumics's main competitors?
Emerging players on record are CardioFocus, Stereotaxis, Acutus Medical and Imricor Medical Systems. Broad incumbents are Medtronic, Boston Scientific, Philips, Biosense Webster (Johnson & Johnson) and Abbott. Intravascular Imaging companies (e.g., Infraredx/Canon, Conavi) is listed as an others.
Does Medlumics have an API?
No public API is recorded for Medlumics.
What industry is Medlumics in?
Medlumics's product category is Cardiac Electrophysiology Medical Devices. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems. Its NAICS code is 334510 and its SIC code is 3841.